CRVL:NASDAQCorVel Corp. Analysis
Data as of 2026-05-26 - not real-time
$62.74
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
CorVel is trading at $62.74, comfortably above its 20‑day SMA of 58.47 and 50‑day SMA of 56.10, indicating short‑term momentum. The 14‑day RSI sits at 63.8, suggesting the stock is approaching overbought territory but still has room for upside. A bullish MACD crossover (MACD line 1.52 above signal 1.05) reinforces the upward bias. Volume is on an increasing trend, supporting the price advance toward the identified resistance of $64.38. However, the 30‑day volatility of nearly 40% and a computed beta of 0.43 signal a price that can swing sharply despite low market‑wide correlation.
Fundamentally, revenue grew 7% to $959 M and EPS rose 17% to $2.14, driven by double‑digit gains in the Network Solutions segment and new payer programs. Operating margins of 15.9% and a ROE of 30.8% reflect strong profitability and capital efficiency. Cash generation remains robust, with operating cash flow of $155 M and free cash flow of $92.9 M, supporting ongoing investments and share repurchases. The balance sheet is conservative, with total debt under $30 M and a debt‑to‑equity of just 7.1. Yet the market values the company at a P/E of 29.3 versus an industry average of 16.8, and the DCF fair value of $36.7 suggests the stock is materially overvalued. The recent earnings release highlighted a 56% jump in quarterly bookings and the rollout of AI‑enabled prepaid solutions, indicating sustainable growth drivers. Given the mix of strong earnings momentum, elevated valuation, and high short‑term price volatility, investors should calibrate exposure accordingly.
Fundamentally, revenue grew 7% to $959 M and EPS rose 17% to $2.14, driven by double‑digit gains in the Network Solutions segment and new payer programs. Operating margins of 15.9% and a ROE of 30.8% reflect strong profitability and capital efficiency. Cash generation remains robust, with operating cash flow of $155 M and free cash flow of $92.9 M, supporting ongoing investments and share repurchases. The balance sheet is conservative, with total debt under $30 M and a debt‑to‑equity of just 7.1. Yet the market values the company at a P/E of 29.3 versus an industry average of 16.8, and the DCF fair value of $36.7 suggests the stock is materially overvalued. The recent earnings release highlighted a 56% jump in quarterly bookings and the rollout of AI‑enabled prepaid solutions, indicating sustainable growth drivers. Given the mix of strong earnings momentum, elevated valuation, and high short‑term price volatility, investors should calibrate exposure accordingly.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Bullish MACD and rising volume
- Price near resistance at $64.38
- Overvalued relative to DCF and industry P/E
Medium Term
1–3 yearsNeutral
Model confidence: 7/10
Key Factors
- 7% revenue growth and 17% EPS increase
- Strong cash flow generation
- Continued valuation premium
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- High ROE and low debt profile
- Secular growth from AI‑enabled prepaid solutions
- Attractive acquisition potential if price corrects toward DCF
Key Metrics & Analysis
Financial Health
Revenue Growth7.40%
Profit Margin11.51%
P/E Ratio29.3
ROE30.81%
ROA15.05%
Debt/Equity7.13
P/B Ratio8.5
Op. Cash Flow$155.6M
Free Cash Flow$92.9M
Industry P/E16.8
Technical Analysis
TrendNeutral
RSI63.8
Support$55.01
Resistance$64.38
MA 20$58.47
MA 50$56.10
MA 200$67.56
MACDBullish
VolumeIncreasing
Fear & Greed Index91.8
Valuation
Fair Value$36.71
GradeOvervalued
TypeGrowth
Risk Assessment
Beta0.43
Volatility39.90%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.